JOSE R. REGUEIRO

PERSONAL HOME PAGE

Bienvenido. Welcome. Willkommen.

Curriculum Vitae

Proyectos

Publicaciones

Servicios

 regueiro@med.ucm.es

 

ABBREVIATED CURRICULUM VITAE (2008)

Personal Data

José R. Regueiro

Born on July 8, 1958 in Santiago (La Coruña)

Permanent adress

Inmunología

 

Facultad de Medicina

 

Universidad Complutense

 

28040 Madrid SPAIN

 

Tel +34 91 394 16 42

 

Fax +34 91 394 16 41

 

regueiro@med.ucm.es

Education

1980

MSc. Biochemistry and Molecular Biology.

Universidad Complutense. Madrid

Languages

English (fluently), French (conversation), German (translation)

 

Specialized education

1981-84

HLA in reproduction and in disease susceptibility. Complement immunogenetics. Department of Immunology (Prof. A. Arnaiz-Villena). Hospital Ramón y Cajal.

1981

Complement allotyping. Centre de Transfusion Sanguine (Dr. G. Hauptman). Strassbourg. France

1982

MSc. Project on complement allotyping. Universidad Complutense. Madrid

1984

Molecular Biology. Centre Hayem (Prof. D. Cohen, Prof. J. Dausset) Hòpital St. Louis. France

1985

ScD, PhD in Immunology. Universidad Complutense. Madrid

1984-86

Immunodeficiencies. Department of Immunology (Prof. A. Arnaiz-Villena). Hospital "12 de Octubre". Madrid

1989

T cell biology. Department of Molecular Immunology. (Prof. C. Terhorst). Dana Farber Cancer Institute. Boston . USA.

 

Positions

1986

Head of the Cellular and Humoral Immunology Laboratory. Department of Immunology (Prof. A. Arnaiz-Villena). Hospital "12 de Octubre". Madrid

1989

Associate Professor of Immunology, School of Medicine, University of Valladolid. Board: Martínes-AC, López de Castro JA, Poljack R. Stutman O, Coutinho A, Rubinstein P, Palacios R, Parkhaus M.

1993

Associate Professor of Immunology, School of Medicine, Universidad Complutense, Madrid.

1995

Head, Center of Immunological Techniques, Universidad Complutense. Madrid

Proyectos financiados

Caracterización de las alteraciones funcionales del linfocito T en una inmunodeficiencia primaria (déficit de IgA) y otra secundaria (mononucleosis infecciosa por Epstein-Barr), FIS, Universidad de Valladolid, 1990-92, 60.000€, Regueiro JR, 5.

Patología del linfocito T en humanos, DGICYT, Universidad Complutense, 1993-95, 133.000€, Regueiro JR, 6.

Fisiopatología del linfocito T en humanos (acción especial), CAM, Univ. Complutense, 1994-95, 25.000€, Regueiro JR, 5.

Establishment of an European network for prevention, diagnosis and treatment of Primary Immunodeficiencies (acción concertada), CEE, varios centros europeos, 1994-96, 338.000 Ecus, A Fisher, 20.
Inmortalización de linfocitos T de individuos con una inmunodeficiencia asociada a Ataxia-Telangiectasia, MEC/ICI, Universidad Complutense y Hospital Nacional de Niños (Costa Rica), 1995-97, 15.000€, Regueiro JR, 4.
Terapia génica in vitro de una inmunodeficiencia humana de CD3, CICYT, Univ. Complutense, 1996-98, 84.000€, Regueiro JR, 6.
Variabilidad del defecto celular en la Inmunodeficiencia Común Variable (IDCV) y su correlación con la clínica, FIS, Univ. Complutense y Hospital La Paz, 1996-98, 66.000€, Mª Cruz Rodríguez, 6.
Reconstitución del funcionamiento de linfocitos T humanos deficientes de CD3gamma. Análisis de una posible terapia génica (acción integrada), MEC, Univ. Complutense y CHU de Purpan (Toulouse, Francia), 1997-98, 2.000€, Regueiro JR, 6.
Inmortalización y caracterización de linfocitos T de individuos con inmunodeficiencia asociada al Síndrome de Chediack-Higashi, MEC/ ICI, Univ. Complutense y Hospital Central San Cristóbal (Tachira, Venezuela), 1998-2000, 18.000€, Regueiro JR, 4.
Inmunodeficiencias humanas: modelos preclínicos de terapia génica somática, CAM, Univ. Complutense, Hospital 12 de Octubre y Centro de Biología Molecular, 1998-2000, 43.000€, Regueiro JR, 8.
Papel biológico de CD3gamma en linfocitos T humanos maduros, DGES, Univ. Complutense, 1999-02, 72.000 €, Regueiro JR, 6.
Papel de la cadena CD3gamma en la construcción del complejo TCR/CD3: caracterización bioquímica del complejo mutante (acción integrada), MEC, Univ. Complutense y CHU de Purpan (Toulouse, Francia), 2000-01, 3.400 €, Regueiro JR, 6.

Análisis clínico/inmunológico del papel de ATM (Ataxia-Telangiectasia Mutated) en linfocitos T humanos, FIS, Universidad Complutense y Hospital Nacional de Niños (Costa Rica), 2000-02, 98.000 €, Regueiro JR, 6.

Papel de los linfocitos T CD8+ en la alergia mediada por anticuerpos IgE, Instituto Danone, Univ. Complutense y Hospital 12 de Octubre, 2001, 6.000 €.Regueiro JR, 6.
Señalización y regulacion del TCR/CD3 en inmunodeficiencias primarias, CAM, Univ. Complutense, 2002-04, 67.110 €, Regueiro JR, 4. Referencia: 8.3/21/2001.1
Reconstitucion, estructura y funcion del complejo TCR/CD3 en linfocitos T maduros deficientes de CD3 gamma, MCYT, Univ. Complutense, 2003-2006, 90.000 €, Regueiro JR, 4. Referencia: BMC 2002/3247

Fisiopatología del complejo TCR/CD3, MECD, Univ. Complutense, 2005-2008, 90000€, Regueiro JR, 6. Referencia: BFU2005-01738

Fisiopatología del complejo TCR/CD3 en ausencia de CD3gamma aproximación a la terapia génica de precursores hematopoyéticos para transplante de médula ósea. FUNDACIÓN MUTUA MADRILEÑA,  Univ. Complutense, 2007-2009,  50.500, Regueiro JR, 8.

Research interests

T lymphocyte physiopathology

Gene Therapy

Signal Transduction

T cell immunodeficiencies

 

Publications

* - First or last authorship

+ - Best five publications

IF- Impact Factor (Science Citation Index)

R - Review

1 HLA factors in non-insulin-dependent diabetes mellitus. Arnaiz-Villena A, Rodriguez Cordoba S, Regueiro JR, Bootello A, Serrano-Rios M. N Eng J Med 303,1065 (1980). IF23

2 Several HLA haplotypic factors for both type 1 (insulin- dependent) and type 2 (non -insulin-dependent) diabetes. Serrano-Rios M, Regueiro JR, Severino R, Lopez-Larrea C, Arnaiz-Villena A. Diabetologia 25, 71 (1983). IF5

3 HLA antigens in insulin dependent and non-insulin dependent Spanish diabetic patients. Serrano-Rios M, Regueiro JR, Severino R, López-Larrea C, Arnaiz-Villena A. Diabete Metab 9(2), 116-120 (1983). IF1

4 Extended HLA haplotypes and Berger's disease. Arnaiz-Villena A, Gonzalo A, Regueiro JR, Vicario JL, Ortuño J. Clin Nephrol 22(6), 320-321 (1984). IF1

5 DR, C4 and Bf allotypes in juvenile rheumatoid arthritis (JRA). Arnaiz-Villena A, Gomez-Reino JJ, Gamir ML, Regueiro JR, Vicario JL, Gomez-Reino FJ, Alonso A, Fernandez-Dapica MP, Irigoyen MV, Mateo I, Zea A. Arthritis Rheum 27, 1281-5 (1984). IF6

6-* HLA typing of dried sperm. Regueiro JR, Arnaiz-Villena A. J Forensic Sci 29, 430-5 (1984). IF2

7-* C3 polymorphism, HLA and chronic renal failure in Spaniards. Regueiro JR, Arnaiz-Villena A. Hum Genet 67, 437-40 (1984). IF3

8-* Immunofixation for C2 typing: C2 allotypes in Spaniards in relation to HLA, Bf and C4. Regueiro JR, Arnaiz-Villena A. Hum Genet 71, 58-61 (1985). IF3

9- HLA-A, -B, -C, Bw4, Bw6 and -DR antigens are expressed on purified seminal cells other than spermatozoa. Rodriguez- Cordoba S, Regueiro JR, Arnaiz-Villena A. Scand J Immunol 24, 545-8 (1986). IF2

10+ Familial defect of CD3 (T3) expression by T cells associated with rare gut epithelial cell autoantibodies. Regueiro JR, Arnaiz-Villena A, O de Landazuri M, Martin-Villa JM, Vicario JL, Pascual-Ruiz V, Guerra-Garcia F, Alcamí J, Lopez-Botet M, Manzanares J. Lancet 1, 1274-5 (1986). IF17

11- Indomethacin in the relief of AIDS symptoms. Ramirez J, Alcami J, Arnaiz-Villena A, Regueiro JR, Rioperez E, Yagüe J, Fernandez F. Lancet 2, 570 (1986). IF17

12* An in vivo functional immune system lacking polyclonal T-cell surface expression of the CD3/Ti(WT31) complex. Regueiro JR, Lopez-Botet M, O de Landazuri M, Alcami J, Corell A, Martin- Villa JM, Vicario JL, Arnaiz-Villena A. Scand J Immunol 26, 699- 707 (1987). IF2

13- Familial defect in the surface expression of the T-cell receptor/CD3 complex. Alarcon B, Regueiro JR, Arnaiz-Villena A, Terhorst C. N Eng J Med 319, 1203-1208 (1988). IF23

14* Human MHC class III (Bf,C2,C4) genes and GLO: their association with other HLA antigens and extended haplotypes in the Spanish population. Regueiro JR, Arnaiz-Villena A.Tissue Antigens 31, 14-27 (1988). IF5

15* Cadaver Kidney transplant in hyperimmunized patients. Andres A, Morales JM, Prieto C, Clerici N, Arnaiz-Villena A, Vicario JL, Alcazar JM, Ruilope LM, Rodicio JL, Regueiro JR. Transpl Proc 20, 73-74 (1988). IF1

16- a/b heterodimeric T-cell receptor expression early in thymocyte differentiation. Toribio ML, Hera A, Regueiro JR, Marquez C, R-Marcos M, Bragado R, Arnaiz-Villena A, Martinez- Alonso C. J Mol Cell Immunol 3, 347-362 (1988). IF2

17* Progress in the classification of severe combined immunodeficiency. Regueiro JR, Perez-Aciego P, Manzanares J, Garcia-Hernandez G, Arnaiz-Villena A. Pediatrics 84, 196-7 (1989). IF3

18- Antigen Society #15 Report (Bw4 and Bw6). Arnaiz-Villena A, Belvedere M, Decary F, Fotino M, Heise E, Hogan V, Martinetti M, Muller C, Richiardi P, Vicario JL, Barbanti M, Bruyere J, Mervart H, Peruccio D, Regueiro JR, Schreuder I. Histocompatibility testing 1987 (Immunobiology of HLA Vol I) Dupont B ed. Springer-Verlag, New York 1989. p214-217

19- RFLP Standardization Report for Class I/MspI. Tonks S, Groves V, Muller C, Otani F, Regueiro JR, Segall M, Bodmer J, Trowsdale J. Histocompatibility testing 1987 (Immunobiology of HLA Vol I) Dupont B ed. Springer-Verlag, New York 1989. p719-20

20- RFLP Standardization Report for Bf/MspI. Tonks S, Groves V, Muller C, Otani F, Regueiro JR, Segall M, Bodmer J, Trowsdale J. Histocompatibility testing 1987 (Immunobiology of HLA Vol I) Dupont B ed. Springer-Verlag, New York 1989. p732-33

21- RFLP Standardization Report for C2/MspI. Tonks S, Groves V, Muller C, Otani F, Regueiro JR, Segall M, Bodmer J, Trowsdale J. Histocompatibility testing 1987 (Immunobiology of HLA Vol I) Dupont B ed. Springer-Verlag, New York 1989. p752-53

22- RFLP Standardization Report for C4/MspI. Tonks S, Groves V, Muller C, Otani F, Regueiro JR, Segall M, Bodmer J, Trowsdale J. Histocompatibility testing 1987 (Immunobiology of HLA Vol I) Dupont B ed. Springer-Verlag, New York 1989. p769-70

23- RFLP Standardization Report for 21OH/MspI. Tonks S, Groves V, Muller C, Otani F, Regueiro JR, Segall M, Bodmer J, Trowsdale J. Histocompatibility testing 1987 (Immunobiology of HLA Vol I) Dupont B ed. Springer-Verlag, New York 1989. p786-87

24- RFLP Standardization Report for DR Alpha/MspI. Tonks S, Groves V, Muller C, Otani F, Regueiro JR, Segall M, Bodmer J, Trowsdale J. Histocompatibility testing 1987 (Immunobiology of HLA Vol I) Dupont B ed. Springer-Verlag, New York 1989. p805-06

25- RFLP Standardization Report for DP Alpha/MspI. Tonks S, Groves V, Muller C, Otani F, Regueiro JR, Segall M, Bodmer J, Trowsdale J. Histocompatibility testing 1987 (Immunobiology of HLA Vol I) Dupont B ed. Springer-Verlag, New York 1989. p846-47

26* Workshop Report of RFLP in C4, C2, BF, and 21OH Genes. Alper C, Andreas-Zietz A, Arnaiz-Villena A, Dawkins R, Keller E, Partanen J, Regueiro JR. Histocompatibility testing 1987 (Immunobiology of HLA Vol I) Dupont B ed. Springer-Verlag, New York 1989. p881-84

27* A novel polyclonal T-cell receptor expression defect probably not linked to HLA. Regueiro JR, Lopez-Botet M, O de Landazuri, Alcami J, Corell A, Martin-Villa JM, Martinez-Laso J, Perez-Aciego P, Vicario JL, Arnaiz-Villena A. Immunobiology of HLA. Vol II: Immunogenetics and Histocompatibility, p555-6, Dupont B ed., Springer-Verlag, New York (1989)

28- An EcoRI polymorphic site in the human complement component C4 genes distinguishes JRA susceptibility-bearing haplotypes. Arnaiz-Villena A, Vicario JL, Martinez-Laso J, Corell A, Regueiro JR, Gomez-Reino FJ, Gomez-Reino JJ. Mol Immunol 26, 427-30 (1989). IF2

29- Description of an HLA-DQA1 RFLP allele (DQalpha4) defining DQw4/DRw8 bearing haplotypes. Martinez-Laso J, Vicario JL, Regueiro JR, Corell A, Artal P, Arnaiz-Villena A. Nucl Acid Res 17, 4006 (1989). IF3

30- A new HLA-DQA1-RFLP allele (DQalpha3b) distinguishes between DQalpha genes of DQw2-DR3 and DQw3-DR5 haplotypes. Martinez-Laso J, Vicario JL, Corell A, Morales P, Regueiro JR, Arnaiz-Villena A. Nucl Acid Res 17, 4911 (1989). IF3

31- Both HLA class II and III restriction length polymorphism factors linked to juvenile rehumatoid arthritis. Vicario JL, Martínez-Laso J, Regueiro JR, Serrano-Rios M, Arnaiz-Villena A. Clin Immunol Immunopathol 56, 22-28 (1990). IF3

32- Reversal of steroid- and antithymocyte globulin-resistant acute rejection crises in renal transplantation with monoclonal antibody (OKT3). Prieto C, Rodríguez-Paternina E, Andrés A, Morales JM, Farias J, Montoyo C, Regueiro JR, Rodicio JL. Transpl Proc 22, 1753-4 (1990). IF1

33* Low IgG2 and polysaccharide response in a T cell receptor expression defect. Regueiro JR, Perez-Aciego P, Aparicio P, Martinez-Alonso C, Morales P, Arnaiz-Villena A. Eur J Immunol 11, 2411-16 (1990). IF6

34- HLA-D determinants are expressed on human seminal cells other than spermatozoa but not on purified spermatozoa. Rodriguez-Cordoba S, Regueiro JR, Arnaiz-Villena A. J Reprod Immunol 18,237-45 (1990). IF2

35R* T-cell receptor immunodeficiency in man. Alarcón B, Perez-Aciego P, Arnaiz- Villena A, Terhorst C, Regueiro JR. Immunodef Rev 2, 1-16 (1990)

36* Differential estimated HLA haplotype frequencies in young and adult insulin- dependent diabetics. Regueiro JR, Martin-Villa JM, Arnaiz- Villena A. Tissue Antigens 36,138-9 (1990). IF5

37- Shared SstI RFLps by HLA-Aw19, A23/24 and A3/11 crossreacting groups. Segurado O, Iglesias P, Vicario JL, Corell A, Regueiro JR, Arnaiz-Villena A. Tissue Antigens 35, 206-210 (1990). IF5

38- Lack of preferential transmission of diabetic HLA alleles by healthy parents to offspring in Spanish diabetic families. Martin-Villa JM, Vicario JL, Martinez-Laso J, Serrano- Rios M, Lledo G, Damiano A, Hawkins F, Regueiro JR, Arnaiz- Villena A. J Clin Endocrin Met 70, 346-8 (1990). IF4

39- Cutaneous lesions in severe combined immunodeficiency: two case reports and a review of the literature. Postigo-Llorente C, Ivars-Amoros J, Ortiz-de Frutos FJ, Regueiro JR, Llamas-Martín R, Guerra-Tapia A, Iglesias-Díez L. Pediatr Dermatol 8,314-21 (1991). IF1

40* Acquired selective signature dysgraphia. Regueiro AM, Segurado OG., Mata P, Regueiro JR. Ann Neurol 31, 115 (1991). IF8

41* A diallelic RFLP of the CD3e chain of the clonotypic T lymphocyte receptor is not associated to certain autoimmune diseases. Timon M, Arnaiz-Villena A, Perez-Aciego P, Morales P, Regueiro JR. Hum Genet 86, 363-364 (1991). IF3

42+ Expression and function of a variant T-cell receptor complex lacking CD3g. Pérez-Aciego P, Alarcón B, Arnaiz-Villena A, Terhorst C, Timón M, Segurado O, Regueiro JR. J. Exp Med 174, 319-326 (1991). IF14

43- T lymphocyte dysfunctions occurring together with apical gut epithelial cell autoantibodies. Martin-Villa JM, Regueiro JR, de Juan D, Perez-Aciego P, Perez-Blas M, Manzanares J, Varela P, Arnaiz-Villena A. Gastroenterology 101, 390-397 (1991). IF7

44* Biochemical basis of a novel T-lymphocyte receptor immunodeficiency by immunohistochemistry: a possible CD3g abnormality. Arnaiz-Villena A., Perez-Aciego P, Ballestín C, Sotelo T, Perez-Seoane C, Martin-Villa JM, Regueiro JR. Lab Invest 64, 675-681 (1991). IF6

45* Impaired T cell signal transduction through CD28 in a patient with idiopathic thrombocytopenia. Pérez-Blas M, Arnaiz-Villena A, Góngora R, Segurado OG, Vivanco JL, Regueiro JR. Clin Exp Immunol 85, 424-428 (1991). IF3

46* T cell function in patients with impaired antibody responses to polysaccharide antigens. Reply. Regueiro JR, Pérez-Aciego P, Timón M, Morales P, Pérez-Blas M, Arnaiz-Villena A. Eur J. Immunol 21, 2293-96 (1991). IF6

47* T-lymphocyte anergy during infectious mononucleosis is restricted to the clonotypic receptor activation pathway. Regueiro JR/Perez-Blas M, Ruiz-Contreras J, Arnaiz-Villena A. Clin Exp Immunol 89, 83-88 (1992). IF3

48+ Primary immunodeficiency caused by mutations in the CD3g subunit of the T-lymphocyte receptor. Arnaiz-Villena A, Timón M, Corell, Pérez-Aciego P, Martín-Villa JM, Regueiro JR. New Eng J Med 327, 529-533 (1992). IF23

49R+ Human T-cell activation deficiencies. Arnaiz-Villena A, Timón M, Rodríguez-Gallego C, Pérez-Blas M, Corell A, Martín-Villa JM, Regueiro JR. Immunology Today 13, 259-265 (1992). IF22

50R* From pathology to physiology of the human T-lymphocyte receptor. Regueiro JR, Timón M, Pérez-Aciego P, Corell A, Martín-Villa JM, Rodríguez-Gallego C, Góngora R, Arnaiz-Villena A. Scand J Immunol 36, 363-369 (1992). IF2

51* CD11b-bearing mononuclear leukocytes and IgA levels in the staging of human immunodeficiency virus infection in Spaniards. Rivera-Guzmán JM, Regueiro JR, Alcamí J, Arnaiz-Villena A. Experientia 48, 402-404 (1992). IF1

52+ Selective disbalances of peripheral blood T lymphocyte subsets in human CD3g deficiency. Timón M, Arnaiz-Villena A, Rodríguez-Gallego C, Pérez-Aciego P, Pacheco A, Regueiro JR. Eur J Immunol 23, 1440-1444 (1993). IF6

53R* T-cell activation. Terhorst C, Regueiro JR. In: Clinical aspects of Immunology (Lachmann PJ, Peters DK, Rosen FS, Walport MJ editors) Blackwell Sci. Pub., Boston, pp447-66 (1993)

54* Selective impairment of T-lymphocyte activation through the T-cell receptor/CD3 complex after cytomegalovirus infection. Timón M, Arnaiz-Villena A, Ruíz-Contreras J, Ramos-Amador JT, Pacheco A, Arnaiz-Villena A. Clin Exp Immunol 94, 38-42 (1993). IF3

55* A decrease in the estimated extended HLA haplotype B18 CF130 DR3 DQw2 is common to non-insulin-dependent diabetes, juveline rheumatoid arthritis and Berger's disease. Regueiro JR, Arnaiz-Villena A, Vicario JL, Martínez-Laso J, Pacheco A. Experientia 49, 324-331 (1993). IF1

56* T lymphocyte signaling defects and immunodeficiency due to the lack of CD3g. Arnaiz-Villena A, Timón M, Rodríguez-Gallego C, Iglesias-Casarrubios P, Regueiro JR. Immunodeficiency 4, 121-129 (1993).

57- Peripheral blood reduction of memory (CD29+, CD45R0+ and "bright" CD2+ and LFA-1+) T lymphocytes in Papillon-Lefévre syndrome. Góngora R, Corell A, Regueiro JR, Carasol M, Rodriguez-Gallego C, Paz-Artal E, Timón M, Allende L, Arnaiz A. Hum Immunol 41,185-192 (1994). IF3

58* Primary T-lymphocyte immunodeficiency associated to a selective impairment of CD2, CD3, CD43 (but not CD28)- mediated signal transduction. Rodriguez-Gallego C, Arnaiz-Villena A, Corell A, Manzanares J, Timón M, Pacheco A, Regueiro JR. Clin Exp Immunol 97,386-391 (1994). IF3

59R* Human T-lymphocyte activation deficiencies. Regueiro J.R, Rodriguez-Gallego C, Arnaiz-Villena A. Medical Intelligence Unit. R.G. Landes Company Pub, Austin, Texas (1994).

60R* Diseases involving the T-cell receptor/CD3 complex. Timón M, Arnaiz Villena A, Rodríguez Gallego C, Pacheco A, Regueiro JR. Crit Rev Oncol Hematol 19, 131-147 (1995). IF2

61R* T-lymphocyte receptor deficiencies. Kappes D, Alarcón B, Regueiro JR. Curr Opin Immunol 7, 441-447 (1995). IF7

62- Diploid expression of HLA class I and II molecules on spermatozoa and their cyclic control by inhibin. Martín-Villa JM, Luque I, Martínez N, Corell A, Regueiro JR, Timón M, Arnaiz-Villena A. Biol Reprod 55, 620-29 (1996). IF3

63* Herpesvirus saimiri transformation of T cells in a CD3g immunodeficiency: phenotypical and functional characterization. Rodriguez-Gallego C, Corell A, Pacheco A, Timón M, Regueiro JR, Allende LM, Madroño A, Arnaiz-Villena A. J Immunol Methods 198, 177-186 (1996). IF2

64* Herpesvirus saimiri immortalization of a b and g d human T-lineage cells derived from CD34+ intrathymic precursors in vitro. Pacheco-Castro A, Márquez C, Toribio ML, Ramiro A, Trigueros C, Regueiro JR. Int. Inmunol 8, 1797-1805 (1996). IF4

65* Construction of retroviral vectors carrying human CD3g cDNA and reconstitution of CD3g expression and T cell receptor surface expression and function in a CD3g-deficient mutant T cell line Sun J, Pacheco-Castro A, Borroto A, Alarcón B, Alvárez Zapata D and Regueiro JR. Hum Gene Therapy 8 (9): 1041-1048 (1997). IF9

66* Phenotypical and functional characterization of Herpesvirus saimiri-immortalized human major histocompatibility complex class II-deficient T lymphocytes. Alvarez-Zapata D, de Miguel-Olalla S, Fontán G, Ferreira A, García-Rodríguez MC, Madero L, van den Elsen P, Regueiro JR. Tissue Antigens, 51: 250-257 (1998)

67ª Model for ATM Heterozygote Identification in a Large Population: Four Founder-Effect ATM Mutations Identify Most of Costa Rican Patients with Ataxia Telangiectasia. Telatar M, Wang Z, Castellvi-Bel S, Tai L-Q, Sheikhavandi S, Regueiro JR, Porras O and Gatti RA. Mol Gen Metab 64, 36-43 (1998)

68* Signaling through a CD3g-deficient T cell antigen receptor/CD3 complex in immortalized CD4+ and CD8+ T lymphocytes. Pacheco-Castro A, Alvárez Zapata D, Serrano-Torres P and Regueiro JR. J Immunol 161, 3152-60 (1998). IF7

69R* CD3 deficiencies. Regueiro JR, Pacheco A, Alvarez-Zapata D, Corell A, Sun JY, Millán R, Arnaiz-Villena A. In: Primary immunodeficiency diseases, a molecular and genetic approach. H. Ochs, J. Puck, E. Smith eds. Oxford University, pp 189-197 (1999)

70* Conformational and biochemical differences in the TCR/CD3 complex of CD8+ vs CD4+ mature lymphocytes revealed in the absence of CD3g. Alvarez D., Pacheco A. , Serrano P., Ramiro A., Toribio ML., Alarcón B., Rubin B., Alibaud L., Regueiro JR. J Biol Chem 274: 35119-28 (1999). IF8

71* CD3 immunodeficiencies. Immunol Allergy. Zapata DA, Pacheco-Castro A, Torres PS, Millán R, Regueiro JR.  Clin 20 (1): 1-17 (2000). IF1

72* ATAXIA-TELANGIECTASIA. A Primary immunodeficiency Revisited. Regueiro J.R, Porras O, Lavin M and Gatti R. Immunol Allergy Clin 20 (1): 177-206 (2000). IF 1

73* Membrane and transmembrane signaling in Herpesvirus saimiri-immortalized CD4+ and CD8+ T lymphocytes is ATM- independent.Rivero ME, Porras O, Pelaez B, Pacheco A. Gatti R, Regueiro JR,  Int Immunol 12: 927-935 (2000). Transmitting editor: T Saito. IF3

74*Characterization of Herpesvirus saimiri-Transformed T Lymphocytes from Common Variable Immunodeficiency Patients.Cabanillas JA, Cambronero R, Pacheco A, García Rodríguez MC, Martín Fernández JM, Fontán G, Regueiro JR.  Clin Exp Immunol 127: 366-373(2002). IF3

75*  T- cell transformation with Herpesvirus saimiri: a tool for primary Immunodeficiencies research. Cabanillas JA, Pachecho Castro A, Zapata DA, Torres PS, Martín Fernández JM, Millán R, Regueiro JR.Recent Res Devel Immunology 4: 381-94 (2002).

76 Apparent genotype-phenotype correlation in childhood, adolescent, and adult Chediak-Higashi syndrome. Karim MA, Suzuki K, Fukai K, Oh J, Nagle DL, Moore KJ, Barbosa E, Falik-Borenstein T, Filipovich A, Ishida Y, Kivrikko S, Klein C, Kreuz F, Levin A, Miyajima H, Regueiro J, Russo C, Uyama E, Vierimaa O, Spritz RA.  Am J Med Genet. 15:16-22 (2002). IF3

77* Contribution of CD3gamma to T-cell receptor regulation and signaling in human mature T lymphocytes.Torres PS, Zapata DA, Pacheco A, Rodríguez-Fernández JL, Cabañas C, Regueiro JR.  Int Immunol 14: 1357-67(2002). Transmitting editor: F Rosen IF3,6

78 Direct Genetic Correction as a New Method for Diagnosis and Molecular Characterization of MHC Class II Deficiency. Matheux F, Ikinciogullari A, Zapata DA, Barras E, Zufferey M, Dogu F, Regueiro JR, Reith W, Villard J. 2002.  Molecular Therapy 6:824-9. IF 5,6

79* Torres PS, Alcover A, Zapata DA, Arnaud J, Pacheco A, Martín-Fernández JM, Villasevil EM, Sanal O, Regueiro JR. TCR dynamics in human mature T lymphocytes lacking CD3g. J Immunol 170: 5947-55  (2003). IF7

80* Toward gene therapy for human CD3 deficiencies.Pacheco-Castro A, Martín-Fernadez JM, Millán R, Sanal O, Allende L, Regueiro JR.  Hum Gene Therapy 14, 1653-61 (2003). IF5

81* Biochemical Differences in the ab TCR·CD3 Surface Complex between CD8+ and CD4+ Human Mature T Lymphocytes.Zapata DA, Schamel WW, Torres PS, Alarcon B, Rossi NE, Navarro MN, Toribio ML, Regueiro JR.  J Biol Chem 279: 24485-92 (2004). IF7

82*Herpesvirus saimiri-transformed CD8+ T cells as a tool to study Chediak-Higashi syndrome cytolytic lymphocytes. Martín-Fernández JM, Cabanillas JA, Rivero M, Lacasa E, Pardo J, Anel A, Rodríguez-Duque PR, Merino F, Rodríguez-Gallego C, Regueiro JR.  J Leukoc Biol 77:661-8 (2005). IF3,6

83* Differential biological role of CD3 chains revealesd by human immunodeficiencies. Recio MJ, Moreno-Pelayo MA, Kiliç SS, Guardo AC, Sanal O,Allende L, Pérez-Flores V, Mencía A, Modamio-Høybjør S, Seoane E, Regueiro JR. J. Immunol. 178(4):2556-64 (2007). IF:7.4

84 Different composition of the human and the mouse gdT cell receptor CD3 explains different phenotypes of CD3g and CD3d immunodeficiencies. Siegers GM, Swamy M, Férnandez-Malavé E, Minguet S., Rathmann S, , Guardo AC, Pérez-Flores V,  Regueiro JR,  Alarcón B, Fischt P, Schamel WWA. J. Exp. Med. 204(11):2537-44 (2007). IF: 13.9.

Servicios

ANÁLISIS INMUNOLÓGICOS

Fenotipo

Función

Inmortalización

Diagnóstico

DIVULGACIÓN CIENTÍFICA

Inmunología

Antonio Arnaiz-Villena, José R. Regueiro y Carlos López Larrea

Editorial Complutense. 1ª Edición. 1995

 

Inmunología. Biología y patología del sistema inmune.

José R. Regueiro, Carlos López Larrea, S. González Rodríguez, E. Martínez Naves.
Editorial Médica Panamericana. 3ª Edición. 2002. Revisada 2004.

Inmunología.

Publicación Oficial de la Sociedad Española de Inmunología

 

 

ASESORÍA INMUNOLÓGICA.

Nuestro departamento ofrece gratuitamente por Internet información inmunológica personalizada a las personas interesadas, pero el plazo para generarla oscila entre 4 meses y 1 año, ya que se basa en el trabajo de los alumnos, que lo realizan como parte de sus prácticas. Para plazos inferiores es necesario cobrar gastos.